ArticleCureus2024
Clinical and Metabolic Characteristics and Follow-Up Results of Adrenal Incidentalomas: A 10-Year Experience.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Low-renin hypertension in incidental adrenal adenomas and response to aldosterone-targeted therapy: a prospective study.European journal of internal medicine · 2026Article
- Article
- A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare.Diseases (Basel, Switzerland) · 2025Article
- Nomogram for predicting postoperative clinical remission of hypertension in patients with adrenal tumors.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn this retrospective study, we aimed to investigate the clinical, hormonal, and radiological characteristics of patients with adrenal incidentalomas (AIs), to assess the prevalence of metabolic syndrome components in patients with AIs, and to determine whether changes in tumor size or hormonal activity occur during long-term follow-up in patients with AIs.
methodsWe retrospectively analyzed data from 384 patients diagnosed with AI between 2010 and 2020. Data regarding radiological, hormonal, and metabolic investigations in diagnosis and also during follow-ups were collected.
resultsA total of 384 patients (248 female, 64%) enrolled in this study. Of them, 348 (90.6%) of the masses were classified as adenomas, 31 (8.07%) as non-adenomas, and four (1.04%) were non-specified. The mean adenoma diameter was approximately 2 cm. Adenomas were found to be mostly on the left side (48.9%). Overall, 13.81% (n = 53) of the tumors were functioning, and among functional adenomas, nine patients (2.34%) had autonomous cortisol secretion, seven subjects (1.82%) had primary hyperaldosteronism, four subjects (1.04%) had pheochromocytomas, and 39 subjects (10.1%) had possible autonomous cortisol secretion. In patients with bilateral incidentalomas, the mean diameter of adenomas was higher than unilateral incidentalomas with a diameter of 24.22 mm in comparison to 20.36 mm (p > 0.05). Similarly, in patients with bilateral incidentalomas, systolic and diastolic blood pressure was higher than in unilateral incidentalomas (135.83 ± 20.27, 130.02 ± 18.84 and 79.25 ± 11.56, 78.52 ± 10.11, respectively, p > 0.05). Moreover, our study revealed that the frequency of diabetes, hypertension, and hyperlipidemia in patients with possible autonomous cortisol secretion was 37%, 63%, and 22.2%, respectively. Of 384 patients, 9.11% (n = 35) underwent surgery. The most common pathological finding was adrenocortical adenoma (n = 19, 54%). The median follow-up duration of patients was 48.91 months. Of 384 patients, 44.7% (n = 172) were followed up regularly with CT/MRI. During the follow-ups, the diameter of adenomas (11.6%) increased by more than 10 mm. Of 384 subjects, 56.7% (n = 218) of patients were followed with hormonal evaluation, six patients had developed possible autonomous cortisol secretion, and three patients had developed autonomous cortisol secretion. Moreover, one subject developed primary hyperaldosteronism.
conclusionsIn this retrospective study, we examined the clinical, radiological, and hormonal profiles of patients with AIs, finding results consistent with existing literature. The conversion to subclinical or clinical hypercortisolism was low, and no new cases of pheochromocytoma were observed, with only one case of primary hyperaldosteronism. Most of the adenomas showed minor growth in size over time, and a small percentage developed hormonal hyperfunctionality. Our study also identified an increased risk of diabetes, hypertension, hyperlipidemia, and metabolic syndrome in AI patients. Additionally, patients with unilateral adenomas had higher triglyceride levels and insulin resistance than those with bilateral adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.